Skip to main content
. Author manuscript; available in PMC: 2020 Dec 14.
Published in final edited form as: Curr Res Transl Med. 2019 Jan 23;67(2):51–55. doi: 10.1016/j.retram.2019.01.001

Figure 1.

Figure 1.

(A) Cumulative incidence of CMV Antigenemia. (B, C, and D) Landmark analysis at day 100 comparing differences in OS, CI of relapse and NRM between patients who experienced CMV reactivation before day 100 and those who did not.